The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1218
September 28, 2005
View Complete Issue         Table of Contents 2019 
Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia
September 28, 2005 (Issue: 1218)
Zmax (Pfizer), an extended-release oral suspension of azithromycin, has been approved by the FDA for single dose treatment of mild to moderate community acquired pneumonia (CAP) and acute bacterial sinusitis (ABS) in adults. Immediate-release...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia
Article code: 1218b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.